Changes in the Plasma Protease Systems During Open-Heart Surgery with Dextran vs. Ringer Acetate as Priming Solution

References

• Aasen A O, Kierulf P, Strømme J H. Methodological considerations on chromogenic peptide substrates assays and application on automated analyzers. Acta Chir Scand 1982; 509: 17–23
   Google Scholar
• Aasen A O, Smith-Erichsen N, Gallimore M J, Amundsen E. Studies on components of the plasma kallikrein-kinin system in plasma samples from normal individuals and patients with septic shock. Advances in shock research, W Schumer, J J Spitzer, B E Marshall. Allan R Liss Inc, New York 1980; 4: 1–10
   Google Scholar
• Bergström K, Egeberg N. Determination of vitamin K sensitive coagulation factors in plasma. Studies on three methods using synthetic chromogenic substrates. Thromb Res 1978; 12: 531–547
   PubMed Web of Science ®Google Scholar
• Bick R L. Hemostasis defects associated with cardiac surgery, prosthetic devices, and other extracorporeal circuits. Semin Thromb Hemost 1985; 11: 249–280
   PubMed Web of Science ®Google Scholar
• Byrick R J, Kay C, Noble W H. Extravascular lung water accumulation in patients following coronary artery surgery. Can Anaesth Soc J 1977; 24: 332–345
   PubMedGoogle Scholar
• Carlin G. Effect of Dextran on fibrinolysis. Ups Dess Fac Med 1980; 365: 7–34
   Google Scholar
• Carlin G, Karlström G, Modig J, Saldeen T. Effect of Dextran on fibrinolysis inhibition activity in the blood after major surgery. Acta Anaesth Scand 1980; 24: 375–378
   PubMed Web of Science ®Google Scholar
• Culliford A T, Thomas S, Spencer F C. Fulminating noncardiogenic pulmonary edema: a newly recognized hazard during cardiac operations. J Thorac Cardiovasc Surg 1980; 80: 866–875
   Web of Science ®Google Scholar
• Fischer M, Wimmer H. Aktivierung des fibrinolytischen Systems durch niedermolekulares Dextran. Bibl Haematol 1965; 23: 1278–1283
   PubMedGoogle Scholar
• Fosse E, Mollnes T E, Ingvaldsen B. Complement activation during major operations with or without cardiopulmonary bypass. J Thorac Cardiovasc Surg 1987; 93: 860–866
   PubMed Web of Science ®Google Scholar
• Friberger P. Chromogenic peptide substrates. Their use for the assay of factors in the fibrinolytic and the plasma kallikrein-kinin systems. Scand J Clin Lab Invest 1982; 42(Suppl 162)
   Google Scholar
• Gothard J WW, Branthwaite M A. Anaesthesia for cardiac surgery and allied procedures. Blackwell Scientific Publications, Oxford 1987; 110–113
   Google Scholar
• Handeland G F, Abildgaard U, Aasen A O. Simplified assay for antithrombin III activity using chromogenic peptide substrate. Scand J Haematol 1983; 31: 427–436
   PubMedGoogle Scholar
• Jespersen J, Rasmussen N R, Sidelmann J. Differences between functional and immunological determinations of plasma antithrombin during the treatment of disseminated intravascular coagulation by infusion of antithrombin-III concentrate. Significance of chromogenic peptide substrate assays in critical care medicine, A O Aasen, E Amundsen, P Kierulf, 1982; 105–107, Acta Chir Scand, Suppl 509
   Google Scholar
• Kazatchine M D, Jouvin M H. Interactions between the alternative complement pathway and the proteases of the coagulation system. Adv Exp Med Biol 1984; 167: 235–239
   PubMed Web of Science ®Google Scholar
• Kongsgaard U E, Smith-Erichsen N, Geiran O, Amunden E, Mollnes T E, Garred P. Different activation patterns in the plasma kallikrein-kinin and complement systems during coronary bypass surgery, Accepted for publication (Acta Anaesthesiol Scand)
   Google Scholar
• Kongsgaard U E, Smith-Erichsen N, Geiran O, Bjørnskau L. Changes in the coagulation and fibrinolytic systems during and after cardiopulmonary bypass surgery, Accepted for publication (Thoracic Cardiovasc Surgeon)
   Google Scholar
• Kluft C, Dooljewaard G, Emeis J J. Role of the contact system in fibrinolysis. Sem Thromb Hemost 1987; 13: 50–68
   PubMed Web of Science ®Google Scholar
• Lindberg H, Svennevig J-L, Vatne K, Lilleaasen P, Abdelnor M. Early postoperative changes with different priming solutions in open-heart surgery. Scand J Thor Cardiovasc Surg 1985; 19: 39–44
   PubMed Web of Science ®Google Scholar
• Ljungström K-G. The antithrombotic efficacy of dextran. Acta Chir Scand 1988; 543: 26–30, (Suppl)
   Google Scholar
• Lumb P D. Comparison between 25% albumen and 6% hydroxyethyl starch solutions on lung water accumulation during and immediately after cardiopulmonary bypass. Ann Surg 1987; 206: 210–213
   PubMed Web of Science ®Google Scholar
• Mammen E F, Koets M H, Washington B C, Wolk L W, Brown J M, Burdick M, Selik N R, Wilson R F. Hemostasis changes during cardiopulmonary bypass surgery. Semin Thromb Hemost 1985; 11: 281–292
   PubMed Web of Science ®Google Scholar
• McKnight C K, Elliot M J, Pearson D T, Holden M P, Alberti K G. The effects of four different crystalloid bypass pump-prime fluids upon the metabolic response to cardiac operation. J Thorac Cardiovasc Surg 1985; 90: 97–111
   PubMed Web of Science ®Google Scholar
• Muzzafar T Z, Stalker A L, Bryce W AJ, Dhall D P. Dextran and fibrin morphology. Nature 1972; 238: 288
   PubMed Web of Science ®Google Scholar
• Müllertz S. Natural inhibitors of fibrinolysis. Progress in chemical fibrinolysis and thrombolysis 3, J F Davidson. Raven Press, New York 1978; 213–237
   Google Scholar
• Popov-Cenic S, Müller N, Kladetzky R-G, Hack G, Lang U, Safer A, Rahlfs V W. Durch Prämedikation, Narkose und Operation bedingte Änderungen des Gerinnungs- und Fibrinolysesystems und der Thrombozyten Einfluss von Dextran und Hydroxyäthylstärke (HÄS) während und nach Operation. Anaesthesist 1977; 26: 77–84
   PubMedGoogle Scholar
• Rosberg B. Blood coagulation during and after normovolemic haemodilution in elective surgery. Ann Clin Res 1981; 13(Suppl 33)84–88
   PubMedGoogle Scholar
• Sade R M, Stroud M R, Crawford F A, Kratz J M, Dearing J P, Bartles D. A prospective randomized study of hydroxyethyl starch, albumin, and lactated Ringer's solution as priming fluid for cardio-pulmonary bypass. J Thorac Cardiovasc Surg 1985; 89: 713–722
   PubMed Web of Science ®Google Scholar
• Saito H. Contact factors in health and disease. Sem Thromb Hemost 1987; 13: 36–49
   PubMed Web of Science ®Google Scholar
• Saldeen T. The microembolism syndrome and dextran. Acta Univ Upps/Symp Univ Upps 1977; 3: 31
   Google Scholar
• Schött U, Sjöstrand U, Thorén T, Berséus O. Three per cent Dextran-60 as plasma substitute in blood component therapy. Acta Anaesthesiol Scand 1985; 29: 767–774
   PubMed Web of Science ®Google Scholar
• Tangen O, Wik K O, Almqvist I AM, Arfors K-E, Hint H C. Effects of dextran on the structure and plasmin induced lysis of human fibrin. Thromb Res 1972; 1: 487–492
   Google Scholar
• van Oeveren W, Kazatchkine M D, Descamps-Latscha B, Maillet F, Fischer E, Carpentier A. Deleterious effects of cardiopulmonary bypass. A prospective study of bubble versus membrane oxygenation. J Thorac Cardiovasc Surg 1985; 89: 888–899
   PubMed Web of Science ®Google Scholar
• Westaby S. Organ dysfunction after cardiopulmonary bypass. A systemic inflammatory reaction initiated by the extracorporeal circuit. Int Care Med 1987; 13: 89–95
   PubMed Web of Science ®Google Scholar
• Åberg M, Hedner U, Bergentz S-E. Effect of Dextran on Factor VIII (Antihemophilic Factor) and platelet function. Ann Surg 1979; 189: 243–247
   PubMed Web of Science ®Google Scholar